These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers. Evans JW; Graves MC; Nugent AC; Zarate CA Sci Rep; 2024 Feb; 14(1):4538. PubMed ID: 38402253 [TBL] [Abstract][Full Text] [Related]
5. Hippocampal subfield volumes predict treatment response to oral ketamine in people with suicidality. Dutton M; Boyes A; Can AT; Mohamed AZ; Hajishafiee M; Shan ZY; Lagopoulos J; Hermens DF J Psychiatr Res; 2024 Jan; 169():192-200. PubMed ID: 38042058 [TBL] [Abstract][Full Text] [Related]
6. Morphological correlates of anxiety-related experiences during a ketamine infusion. Graf S; Dörl G; Milz C; Kathofer M; Stöhrmann P; Gomola D; Briem E; Schlosser G; Mayerweg A; Semmelweis-Tomits J; Hoti A; Eggerstorfer B; Schmidt C; Crone J; Rujescu D; Spies M; Lanzenberger R; Spurny-Dworak B World J Biol Psychiatry; 2024 Nov; 25(9):537-546. PubMed ID: 39394769 [TBL] [Abstract][Full Text] [Related]
7. Hippocampal subfield volumes in treatment resistant depression and serial ketamine treatment. Zavaliangos-Petropulu A; McClintock SM; Joshi SH; Taraku B; Al-Sharif NB; Espinoza RT; Narr KL Front Psychiatry; 2023; 14():1227879. PubMed ID: 37876623 [TBL] [Abstract][Full Text] [Related]
8. Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants. Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA Biol Psychiatry Cogn Neurosci Neuroimaging; 2019 Jul; 4(7):610-618. PubMed ID: 30826253 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of ketamine action as an antidepressant. Zanos P; Gould TD Mol Psychiatry; 2018 Apr; 23(4):801-811. PubMed ID: 29532791 [TBL] [Abstract][Full Text] [Related]
10. Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression. Burrows M; Kotoula V; Dipasquale O; Stringaris A; Mehta MA J Psychopharmacol; 2023 Aug; 37(8):784-794. PubMed ID: 37491833 [TBL] [Abstract][Full Text] [Related]
11. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Zhou W; Wang N; Yang C; Li XM; Zhou ZQ; Yang JJ Eur Psychiatry; 2014 Sep; 29(7):419-23. PubMed ID: 24321772 [TBL] [Abstract][Full Text] [Related]
12. Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Moaddel R; Shardell M; Khadeer M; Lovett J; Kadriu B; Ravichandran S; Morris PJ; Yuan P; Thomas CJ; Gould TD; Ferrucci L; Zarate CA Psychopharmacology (Berl); 2018 Oct; 235(10):3017-3030. PubMed ID: 30116859 [TBL] [Abstract][Full Text] [Related]
13. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities. Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761 [TBL] [Abstract][Full Text] [Related]
14. Sex Differences in the Temporal Neuromolecular and Synaptogenic Effects of the Rapid-acting Antidepressant Drug Ketamine in the Mouse Brain. Thelen C; Flaherty E; Saurine J; Sens J; Mohamed S; Pitychoutis PM Neuroscience; 2019 Feb; 398():182-192. PubMed ID: 30537521 [TBL] [Abstract][Full Text] [Related]
15. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA Neural Plast; 2015; 2015():858251. PubMed ID: 26137324 [TBL] [Abstract][Full Text] [Related]
16. Extrasynaptic CaMKIIα is involved in the antidepressant effects of ketamine by downregulating GluN2B receptors in an LPS-induced depression model. Tang XH; Zhang GF; Xu N; Duan GF; Jia M; Liu R; Zhou ZQ; Yang JJ J Neuroinflammation; 2020 Jun; 17(1):181. PubMed ID: 32522211 [TBL] [Abstract][Full Text] [Related]
17. Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression. Tai HH; Cha J; Vedaei F; Dunlop BW; Craighead WE; Mayberg HS; Choi KS Front Psychiatry; 2021; 12():718539. PubMed ID: 35002790 [No Abstract] [Full Text] [Related]
18. Alterations in hippocampal subfield volumes among schizophrenia patients, their first-degree relatives and healthy subjects. Ohi K; Nemoto K; Kataoka Y; Sugiyama S; Muto Y; Shioiri T; Kawasaki Y Prog Neuropsychopharmacol Biol Psychiatry; 2021 Aug; 110():110291. PubMed ID: 33662534 [TBL] [Abstract][Full Text] [Related]
19. Guanosine boosts the fast, but not sustained, antidepressant-like and pro-synaptogenic effects of ketamine by stimulating mTORC1-driven signaling pathway. Camargo A; Dalmagro AP; Delanogare E; Fraga DB; Wolin IAV; Zeni ALB; Brocardo PS; Rodrigues ALS Eur Neuropsychopharmacol; 2022 Apr; 57():15-29. PubMed ID: 35008015 [TBL] [Abstract][Full Text] [Related]
20. Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control. Höflich A; Ganger S; Tik M; Hahn A; Kranz GS; Vanicek T; Spies M; Kraus C; Windischberger C; Kasper S; Winkler D; Lanzenberger R Neuroimage; 2017 Feb; 147():198-203. PubMed ID: 27986606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]